I think the most interesting question here is: does UK AISI's loss of access portend limited commercial model access for non-US customers? Could European pharma firms be withheld BioMythos access while US firms develop next-gen drugs? I think yes. Commercial frontier access is very costly to sustain; first for misuse and distillation concerns, eventually also for shortages in inference compute. The question is who makes the cut. The hope was that US allies - in particular the UK - could just…